Mechanistic investigations have revealed the impact of metformin on AD etiology and pathophysiology, encompassing neuronal loss, neural dysfunction, tau phosphorylation, Aβ deposition, chronic neuroinflammation, insulin resistance, altered glucose metabolism, and mitochondrial dysfunction [172]. The gene discussed is MAPT; the disease is Alzheimer disease.